{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T22:27:55Z","timestamp":1787351275783,"version":"build-2736575974"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jpeds.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pediatrics"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.jpeds.2022.11.026","type":"journal-article","created":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T20:11:20Z","timestamp":1669839080000},"page":"224-229.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Safety and Feasibility of Riociguat Therapy for the Treatment of Chronic Pulmonary Arterial Hypertension in Infancy"],"prefix":"10.1016","volume":"255","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6227-6761","authenticated-orcid":false,"given":"Regan E.","family":"Giesinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy H.","family":"Stanford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brady","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven H.","family":"Abman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick J.","family":"McNamara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpeds.2022.11.026_bib1","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/ppe.12444","article-title":"Identification of gaps in the current knowledge on pulmonary hypertension in extremely preterm infants: A systematic review and meta-analysis","volume":"32","author":"Arjaans","year":"2018","journal-title":"Paediatr Perinat Epidemiol"},{"key":"10.1016\/j.jpeds.2022.11.026_bib2","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1542\/peds.2007-0971","article-title":"Pulmonary artery hypertension in formerly premature infants with bronchopulmonary dysplasia: clinical features and outcomes in the surfactant era","volume":"120","author":"Khemani","year":"2007","journal-title":"Pediatrics"},{"key":"10.1016\/j.jpeds.2022.11.026_bib3","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1542\/peds.65.3.529","article-title":"Value of echocardiography in assessing the outcome of bronchopulmonary dysplasia of the newborn","volume":"65","author":"Fouron","year":"1980","journal-title":"Pediatrics"},{"key":"10.1016\/j.jpeds.2022.11.026_bib4","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1136\/adc.65.7.739","article-title":"Changes in pulmonary circulation in severe bronchopulmonary dysplasia","volume":"65","author":"Bush","year":"1990","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.jpeds.2022.11.026_bib5","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1086\/674762","article-title":"Safety of epoprostenol and treprostinil in children less than 12 months of age","volume":"3","author":"McIntyre","year":"2013","journal-title":"Pulm Circ"},{"key":"10.1016\/j.jpeds.2022.11.026_bib6","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1097\/01.inf.0000108191.13799.09","article-title":"Predisposition of infants with chronic lung disease to respiratory syncytial virus-induced respiratory failure: a vascular hypothesis","volume":"23","author":"Carpenter","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.jpeds.2022.11.026_bib7","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s00431-015-2515-7","article-title":"Sildenafil therapy in bronchopulmonary dysplasia-associated pulmonary hypertension: a retrospective study of efficacy and safety","volume":"174","author":"Tan","year":"2015","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.jpeds.2022.11.026_bib8","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1053\/j.semperi.2018.09.005","article-title":"An update on the diagnosis and management of bronchopulmonary dysplasia (BPD)-associated pulmonary hypertension","volume":"42","author":"Berkelhamer","year":"2018","journal-title":"Semin Perinatol"},{"key":"10.1016\/j.jpeds.2022.11.026_bib9","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.echo.2011.07.014","volume":"24","author":"Mertens","year":"2011","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.jpeds.2022.11.026_bib10","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/nrd2038","article-title":"NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential","volume":"5","author":"Evgenov","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jpeds.2022.11.026_bib11","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00408-018-0100-3","article-title":"Real-world switching to riociguat: Management and Practicalities in Patients with PAH and CTEPH","volume":"196","author":"Gall","year":"2018","journal-title":"Lung"},{"key":"10.1016\/j.jpeds.2022.11.026_bib12","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ijcard.2018.07.015","article-title":"Sequential treatment with sildenafil and riociguat in patients with persistent or inoperable chronic thromboembolic pulmonary hypertension improves functional class and pulmonary hemodynamics","volume":"269","author":"Darocha","year":"2018","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jpeds.2022.11.026_bib13","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1136\/heartjnl-2016-309621","article-title":"Haemodynamic effects of riociguat in inoperable\/recurrent chronic thromboembolic pulmonary hypertension","volume":"103","author":"Kim","year":"2017","journal-title":"Heart"},{"key":"10.1016\/j.jpeds.2022.11.026_bib14","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/978-3-540-68964-5_13","article-title":"NO-independent, haem-dependent soluble guanylate cyclase stimulators","author":"Stasch","year":"2009","journal-title":"Handb Exp Pharmacol"},{"key":"10.1016\/j.jpeds.2022.11.026_bib15","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.lfs.2005.06.029","article-title":"Disturbances in nitric oxide\/cyclic guanosine monophosphate system in SHR\/NDmcr-cp rats, a model of metabolic syndrome","volume":"78","author":"Kagota","year":"2006","journal-title":"Life Sci"},{"key":"10.1016\/j.jpeds.2022.11.026_bib16","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3317\/jraas.2003.014","article-title":"Interactions of angiotensin II with NAD(P)H oxidase, oxidant stress and cardiovascular disease","volume":"4","author":"Harrison","year":"2003","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"10.1016\/j.jpeds.2022.11.026_bib17","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1164\/rccm.200411-1587OC","article-title":"Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells","volume":"172","author":"Wharton","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jpeds.2022.11.026_bib18","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1161\/CIRCULATIONAHA.105.581405","article-title":"Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling","volume":"113","author":"Dumitrascu","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jpeds.2022.11.026_bib19","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1161\/01.CIR.0000055737.15443.F8","article-title":"Cardiorenal and humoral properties of a novel direct soluble guanylate cyclase stimulator BAY 41-2272 in experimental congestive heart failure","volume":"107","author":"Boerrigter","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jpeds.2022.11.026_bib20","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1053\/j.semperi.2015.12.005","article-title":"Hemodynamic instability in the critically ill neonate: an approach to cardiovascular support based on disease pathophysiology","volume":"40","author":"Giesinger","year":"2016","journal-title":"Semin Perinatol"},{"key":"10.1016\/j.jpeds.2022.11.026_bib21","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(02)11024-5","article-title":"Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial","volume":"360","author":"Ghofrani","year":"2002","journal-title":"Lancet"}],"container-title":["The Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022347622010794?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022347622010794?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:14:52Z","timestamp":1758359692000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022347622010794"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":21,"alternative-id":["S0022347622010794"],"URL":"https:\/\/doi.org\/10.1016\/j.jpeds.2022.11.026","relation":{},"ISSN":["0022-3476"],"issn-type":[{"value":"0022-3476","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and Feasibility of Riociguat Therapy for the Treatment of Chronic Pulmonary Arterial Hypertension in Infancy","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pediatrics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpeds.2022.11.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}